Screen fewer compounds with diversified scaffolds
Analyze your target and optimize your HTS screening compound library to your target of interest in just a couple of weeks.
Identify off-targets of your compound
De-risk and get control over potential complications at an early stage.
A Knowledge-Based Approach
Our disruptive software technology identifies drug candidates based on the geometry of protein binding sites and their drug-target interactions, paving new ways to explore the drug-target space at a ground-breaking level of precision.
- Predictions based on 3D protein structure & binding affinity data.
- Exploits hidden knowledge in vast numbers of protein-ligand complexes found in the Protein Data Bank (PDB).
- Delivers high scaffold diversity.
- Off-target identification.
Explore pharmAI’s unique accelerated hit finding service
Case study: binders to cGMPdependent 3',5'-cyclic phosphodiesterase (PDE2)
pharmAI’s DiscoveryEngine scored 125 compounds from a library of 2M compounds, spread across the chemical space. After in vitro validation, seven compounds showed binding to PDE2 (at a hit rate of almost 6%) of which three showed affinities in the lower micromolar range.
Deep Learning for Predictions
Our Artificial Intelligence (AI) initiative opens the door to new compound classes. We use classical AI methods with the combination of Deep Learning to predict binding affinity and to improve the quality of our algorithm’s output. Our aim is a quicker and cheaper drug discovery while keeping high precision. In addition, our algorithms are getting smarter throughout the time in a semi-supervised manner.
Off-target identification service at an early stage of drug discovery
Case study: Prediction of MAPK14 Off-Targets
Using PharmAI's DiscoveryEngine, 13 off-targets were identified and further validated in the laboratory tests in collaboration with 2bind GmbH. Of the 13 tested proteins, binding was observed for six which corresponds to an extraordinarily high hit rate of 46 percent.
Delivering High-Quality Results, Rapidly
We invested 500 CPU years of pre-computation to deliver your results rapidly. Our efficient algorithms make use of this data resource and run magnitudes faster than traditional virtual screening.
- Fast turnaround for screening library focus, off-target prediction & scaffold diversification
- Systematic similarity screens across large databases
- Exceptionally high success rates
Protein-Ligand Interaction Profiler (PLIP)
You can also read and follow the latest development of PLIP in our blog.
Blog / Support
Why should you choose PharmAI?
There are many reasons for choosing us as your partner in your drug discovery journey.